Andere Sprachen Vivos Therapeutics, Inc.

Aktien

A3EWWY

US92859E2072

VVOS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.06.2024			% 5 Tage	% 1. Jan.
2,22 ^USD	-7,11 %		-0,45 %	-82,15 %

27.06.	Vivos Therapeutics gibt positive Ergebnisse eines 7-monatigen standortübergreifenden Pilotprojekts für sein neues anbieterbasiertes Marketing- und Vertriebsmodell bekannt	CI
14.06.	VSI Providers, PLLC, eine hundertprozentige Tochtergesellschaft von Vivos Therapeutics, Inc. und Rebis Health Holdings, LLC schließen einen Vertrag über eine strategische Allianz ab, der eine gemeinsame Marketing- und Vertriebsvereinbarung vorsieht	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model	27.06.
Vivos Therapeutics Announces Positive Results from 7-Month Multi-Site Pilot of Its New Provider-Based Marketing and Distribution Model	27.06.
VSI Providers, PLLC, a Wholly-Owned Subsidiary of Vivos Therapeutics, Inc. and Rebis Health Holdings, LLC Enter into A Strategic Alliance Agreement Providing for A Joint Marketing and Distribution Arrangement	14.06.
Vivos Therapeutics, Inc. Announces the Execution of A Strategic Marketing and Distribution Alliance with an Operator of Multiple Sleep Testing and Treatment Centers in Colorado	14.06.
Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance	12.06.
Vivos Therapeutics, Inc. announced that it has received $7.5 million in funding	10.06.
Vivos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
Earnings Flash (VVOS) VIVOS THERAPEUTICS Reports Q1 Revenue $3.4M	14.05.
Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update	14.05.
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call	14.05.
Vivos Therapeutics : Material Event - Form 8-K	06.05.
Vivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical Devices	09.04.
Vivos Therapeutics : rsquo; Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement	09.04.
Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures	01.04.
Top Premarket Decliners	01.04.
Vivos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Earnings Flash (VVOS) VIVOS THERAPEUTICS Posts Q4 Revenue $3.2M	28.03.
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update	28.03.
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call	28.03.
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds	15.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Vivos Therapeutics, Inc.

Aktien

A3EWWY

US92859E2072

VVOS

Andere Sprachen

Filter